Nephrolithiasis on indinavir.

PubMed · 10557573

Nephrolithiasis on indinavir.

Abstract

(1) Nephrolithiasis is found in 4-13% of patients treated with indinavir, an HIV protease inhibitor. Most of these stones are composed of indinavir. (2) Outcome is often favourable, with simple passage of the stone, but endoscopic or surgical treatment is sometimes required. (3) Crystalluria seems to be more frequent, but is often asymptomatic. (4) Prevention is based on fluid intake of at least 1.5 litres a day. Indinavir withdrawal may be necessary.

Explore related subjects

HIV Protease Inhibitors Humans Indinavir Kidney Calculi Treatment Outcome Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

1999. Nephrolithiasis on indinavir.. https://pubmed.ncbi.nlm.nih.gov/10557573/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios.

Explore the source record for details and available documents.

HIV Protease Inhibitors↗

PubMed2001

Two sulfonamides-containing dihydropyrone derivatives as HIV protease inhibitors.

Explore the source record for details and available documents.

HIV Protease Inhibitors↗

PubMed2001

Lopinavir-Ritonavir: a new protease inhibitor.

Lopinavir is a new protease inhibitor that is structurally related to ritonavir. It recently was approved by the Food and Drug Administration as a coformulation with ritonavir under the brand name Kaletra. Ritonavir substantially increases lopinavir drug exposure by inhibiting cytochrome P450 isoenzyme 3A4. Based on limited data, lopinavir-ritonavir demonstrates safety and efficacy in both antiretroviral-naive and protease inhibitor-experienced patients. It has the ability to durably suppress human immunodeficiency virus (HIV) RNA for up to 2 years in antiretroviral-naïve patients. Compared with nelfinavir, it had superior virologic control at 48 weeks in antiretroviral-naïve patients. Its side effects include diarrhea, abnormal stools, abdominal pain, nausea, vomiting, and asthenia. A number of patients experienced grade 3-4 laboratory abnormalities in liver function tests, cholesterol, and triglycerides while receiving this drug combination. The exact resistance patterns of lopinavir-ritonavir are unknown, but the Department of Health and Human Services strongly recommends it for the initial treatment of HIV-infected adults and adolescents.

HIV Protease Inhibitors↗